Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.

Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Sarshekeh AM, Bressler J, Lopez DS, Daniel CR, Swartz MD, Kopetz S.

Transl Oncol. 2018 Jul 30;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. [Epub ahead of print]

2.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jul 3. doi: 10.1093/annonc/mdy221. [Epub ahead of print] No abstract available.

PMID:
29982323
3.

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.

Mehrvarz Sarshekeh A, Xiong HQ, Iizuka K, Hochster HS, Kopetz S.

Invest New Drugs. 2018 Jun 13. doi: 10.1007/s10637-018-0615-8. [Epub ahead of print]

PMID:
29948357
4.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
5.

How should BRAF V600E-mutated colorectal cancer be treated?

Kopetz S.

Clin Adv Hematol Oncol. 2018 May;16(5):333-335. No abstract available.

PMID:
29851929
6.

RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.

Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C.

Ann Surg Oncol. 2018 Aug;25(8):2457-2466. doi: 10.1245/s10434-018-6517-3. Epub 2018 May 21.

PMID:
29786130
7.

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG.

Front Oncol. 2018 Apr 20;8:107. doi: 10.3389/fonc.2018.00107. eCollection 2018. Review.

8.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
9.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Apr 27. doi: 10.1093/jnci/djy067. [Epub ahead of print]

PMID:
29718453
10.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

PMID:
29710228
11.

Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Apr 23;19(5):25. doi: 10.1007/s11864-018-0537-x.

PMID:
29687230
12.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

PMID:
29668571
13.

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S.

Invest New Drugs. 2018 Apr 18. doi: 10.1007/s10637-018-0602-0. [Epub ahead of print]

PMID:
29667134
14.

Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases.

Okuno M, Goumard C, Mizuno T, Kopetz S, Omichi K, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Conrad C.

Br J Surg. 2018 Apr 17. doi: 10.1002/bjs.10822. [Epub ahead of print]

PMID:
29664996
15.

Biomarkers in colorectal liver metastases.

Yamashita S, Chun YS, Kopetz SE, Vauthey JN.

Br J Surg. 2018 May;105(6):618-627. doi: 10.1002/bjs.10834. Epub 2018 Mar 26. Review.

PMID:
29579319
16.

SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.

Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE, Maru D, Conrad C, Tzeng CD, Wei SH, Aloia TA, Vauthey JN.

Eur J Surg Oncol. 2018 May;44(5):684-692. doi: 10.1016/j.ejso.2018.02.247. Epub 2018 Mar 7.

PMID:
29551247
17.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.

Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R.

Oncotarget. 2017 Oct 24;9(12):10259-10271. doi: 10.18632/oncotarget.21982. eCollection 2018 Feb 13.

18.

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.

Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X, Goel A.

Clin Cancer Res. 2018 Mar 7. doi: 10.1158/1078-0432.CCR-17-3236. [Epub ahead of print]

PMID:
29514841
19.

Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Lima AAP, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Feb 27;19(2):11. doi: 10.1007/s11864-018-0524-2. Review. Erratum in: Curr Treat Options Oncol. 2018 Apr 23;19(5):25.

PMID:
29488033
20.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Sarshekeh AM, Overman MJ, Kopetz S.

Future Oncol. 2018 Aug;14(18):1869-1874. doi: 10.2217/fon-2017-0696. Epub 2018 Feb 23.

PMID:
29473436
21.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12.

22.

Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases.

Odisio BC, Yamashita S, Huang SY, Kopetz SE, Ahrar K, Mizuno T, Conrad C, Aloia TA, Chun YS, Gupta S, Vauthey JN.

J Vasc Interv Radiol. 2018 Mar;29(3):395-403.e1. doi: 10.1016/j.jvir.2017.10.026. Epub 2018 Feb 1.

PMID:
29395898
23.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
24.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Jan 15. doi: 10.1093/jnci/djx288. [Epub ahead of print]

PMID:
29346573
25.

Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

Korphaisarn K, Chou CK, Xia WY, Clarke CN, Katkhuda R, Davis JS, Raghav KP, Liao HW, Wu JY, Menter DG, Maru DM, Hung MC, Kopetz S.

Am J Cancer Res. 2017 Dec 1;7(12):2587-2599. eCollection 2017.

26.

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.

Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.

PMID:
29196463
27.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

PMID:
29180604
28.

Integrated safety summary for trifluridine/tipiracil (TAS-102).

Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, Yoshino T.

Anticancer Drugs. 2018 Jan;29(1):89-96. doi: 10.1097/CAD.0000000000000554.

PMID:
29176395
29.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
30.

Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis.

Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME, Kaur H, Maru DM, Skibber JM, Rodriguez-Bigas MA, You YN, Krishnan S, Chang GJ.

Adv Radiat Oncol. 2017 Apr 12;2(3):455-464. doi: 10.1016/j.adro.2017.04.001. eCollection 2017 Jul-Sep.

31.

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.

Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S.

Gut. 2018 Jun;67(6):1095-1102. doi: 10.1136/gutjnl-2017-313786. Epub 2017 Oct 30.

PMID:
29084828
32.

Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS; BIG-RENAPE Working Group.

Ann Surg Oncol. 2018 Jan;25(1):179-187. doi: 10.1245/s10434-017-6141-7. Epub 2017 Oct 25.

PMID:
29071660
33.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688.

PMID:
29069279
34.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

35.

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT.

Cancer. 2018 Jan 15;124(2):315-324. doi: 10.1002/cncr.31044. Epub 2017 Oct 4.

PMID:
28976556
36.

Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.

Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S.

Ann Surg Oncol. 2017 Dec;24(13):4051-4058. doi: 10.1245/s10434-017-6054-5. Epub 2017 Sep 21.

PMID:
28936799
37.

Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases.

Conrad C, Vauthey JN, Masayuki O, Sheth RA, Yamashita S, Passot G, Bailey CE, Zorzi D, Kopetz S, Aloia TA, You YN.

Ann Surg Oncol. 2017 Dec;24(13):3857-3864. doi: 10.1245/s10434-017-6089-7. Epub 2017 Sep 19.

PMID:
28929463
38.

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.

Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S.

Oncotarget. 2017 Jun 3;8(34):57882-57888. doi: 10.18632/oncotarget.18357. eCollection 2017 Aug 22.

39.

Metastasis of cancer: when and how?

Lee WC, Kopetz S, Wistuba II, Zhang J.

Ann Oncol. 2017 Sep 1;28(9):2045-2047. doi: 10.1093/annonc/mdx327. No abstract available.

PMID:
28911075
40.

Clinical utility of circulating cell-free DNA in advanced colorectal cancer.

Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V.

PLoS One. 2017 Aug 29;12(8):e0183949. doi: 10.1371/journal.pone.0183949. eCollection 2017.

41.

Recent developments in the treatment of metastatic colorectal cancer.

Loree JM, Kopetz S.

Ther Adv Med Oncol. 2017 Aug;9(8):551-564. doi: 10.1177/1758834017714997. Epub 2017 Jun 29. Review.

42.

Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.

Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN.

Ann Surg. 2017 Aug 1. doi: 10.1097/SLA.0000000000002450. [Epub ahead of print]

PMID:
28767562
43.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.

PMID:
28734759
44.

Platelet "first responders" in wound response, cancer, and metastasis.

Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV.

Cancer Metastasis Rev. 2017 Jun;36(2):199-213. doi: 10.1007/s10555-017-9682-0. Review.

45.

Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development.

Kumar R, Herold JL, Schady D, Davis J, Kopetz S, Martinez-Moczygemba M, Murray BE, Han F, Li Y, Callaway E, Chapkin RS, Dashwood WM, Dashwood RH, Berry T, Mackenzie C, Xu Y.

PLoS Pathog. 2017 Jul 13;13(7):e1006440. doi: 10.1371/journal.ppat.1006440. eCollection 2017 Jul.

46.

The potential role of platelets in the consensus molecular subtypes of colorectal cancer.

Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG.

Cancer Metastasis Rev. 2017 Jun;36(2):273-288. doi: 10.1007/s10555-017-9678-9. Review.

PMID:
28681242
47.

Platelets, circulating tumor cells, and the circulome.

Kanikarla-Marie P, Lam M, Menter DG, Kopetz S.

Cancer Metastasis Rev. 2017 Jun;36(2):235-248. doi: 10.1007/s10555-017-9681-1. Review.

PMID:
28667367
48.

Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.

Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ.

J Clin Oncol. 2017 Aug 10;35(23):2631-2638. doi: 10.1200/JCO.2016.72.1464. Epub 2017 Jun 28.

49.

Global and targeted serum metabolic profiling of colorectal cancer progression.

Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, Ye Y, Liang D, Wu X.

Cancer. 2017 Oct 15;123(20):4066-4074. doi: 10.1002/cncr.30829. Epub 2017 Jun 22.

PMID:
28640361
50.

The somatic mutation landscape of premalignant colorectal adenoma.

Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X.

Gut. 2018 Jul;67(7):1299-1305. doi: 10.1136/gutjnl-2016-313573. Epub 2017 Jun 12.

Supplemental Content

Loading ...
Support Center